Pharmacodynamic monitoring by residual gene expression of the nuclear factor of activated T cell-regulated genes in lung transplant recipients and its correlation with tacrolimus blood levels.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 05 02 2024
accepted: 22 04 2024
medline: 27 5 2024
pubmed: 27 5 2024
entrez: 27 5 2024
Statut: epublish

Résumé

Trough blood levels (C NFAT-RGE and tacrolimus C Tacrolimus C Consequently, a subset of patients within the tacrolimus therapeutic range may be more susceptible to infection or cancer, potentially benefiting from NFAT-RGE and tacrolimus peak level monitoring to tailor their dosage. Further quantitative risk assessment studies are needed to elucidate the relationship between NFAT-RGE and the risk of infection, cancer, or rejection.

Identifiants

pubmed: 38799459
doi: 10.3389/fimmu.2024.1382459
pmc: PMC11116644
doi:

Substances chimiques

Tacrolimus WM0HAQ4WNM
NFATC Transcription Factors 0
Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1382459

Informations de copyright

Copyright © 2024 Boada-Pérez, Ruiz de Miguel, Erro, Ussetti, Aguilar, Castejón, Rosado, Escobar-Fornieles, Revilla-López, Bravo, Sáez-Giménez, Zapata-Ortega, Villena-Ortiz, Vima-Bofarull, Monforte and Gómez-Ollés.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer OM declared a shared affiliation, with no collaboration, with some of the authors CB, VM, SG-O to the handling editor at the time of the review.

Auteurs

Meritxell Boada-Pérez (M)

Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Department of Pulmonology, Vall d'Hebron Institut de Recerca, Barcelona, Spain.

Victoria Ruiz de Miguel (V)

Department of Pulmonology, Vall d'Hebron Institut de Recerca, Barcelona, Spain.

Marta Erro (M)

Department of Pulmonary Medicine, University Hospital Puerta de Hierro, Madrid, Spain.

Piedad Ussetti (P)

Department of Pulmonary Medicine, University Hospital Puerta de Hierro, Madrid, Spain.

Myriam Aguilar (M)

Department of Pulmonary Medicine, University Hospital Puerta de Hierro, Madrid, Spain.

Raquel Castejón (R)

Internal Medicine Laboratory, Instituto de Investigación Puerta de Hierro Segovia de Arana, Madrid, Spain.

Silvia Rosado (S)

Internal Medicine Laboratory, Instituto de Investigación Puerta de Hierro Segovia de Arana, Madrid, Spain.

Roser Escobar-Fornieles (R)

Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Eva Revilla-López (E)

Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Carlos Bravo (C)

Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Berta Sáez-Giménez (B)

Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain.

Marta Zapata-Ortega (M)

Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Yolanda Villena-Ortiz (Y)

Central Laboratory Services, Pharmacology Section, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Jaume Vima-Bofarull (J)

Central Laboratory Services, Pharmacology Section, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Víctor Monforte (V)

Department of Pulmonology, Lung Transplant Program, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Susana Gómez-Ollés (S)

Department of Pulmonology, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH